GALDERMA Committed to the future of Dermatology Read more ...
Talent Working at GaldermaRead more ...
FOCUSED Patients at the heart of everything we doRead more ...
PARTNER With Healthcare Professionals around the WorldRead more ...
You are here » News
Paris (France) and Lausanne (Switzerland), 6 December 2007 - Ipsen (Euronext: FR0010259150; IPN), an innovation-driven, international specialty pharmaceutical group, and Galderma, a leading global pharmaceutical company focused on dermatology, today announced that they have entered into a new partnership for the exclusive promotion and distribution of Ipsen's Dysport®, the company's botulinum toxin type A product, for use in aesthetic medicine and dermatological indications in Brazil, Argentina and Paraguay.
Read more...
Posted in: Press release
Fort Worth, TX – July 17, 2007 – Galderma Laboratories, L.P. has published the second edition of the Galderma Quality Report for Dermatology & Managed Care. This insightful report is provided complimentary as an educational service of Galderma, a leading worldwide dermatology company, as a follow-up to the inaugural Quality Report issued in 2005.
Fort Worth, Texas, June 20, 2007 /PRNewswire/ - Galderma Laboratories, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved Differin(R) (adapalene) Gel, 0.3%, a new, higher concentration formulation of Differin(R) (adapalene) 0.1%, a topical retinoid indicated for the treatment of acne. Differin(R) Gel, 0.3% provides physicians with a more potent formulation of adapalene that is efficacious enough to treat moderate to moderately-severe acne while still providing a favorable side effect profile. Differin(R) Gel, 0.3% will be available by prescription by July 2007.
The Galderma Global Corporate Campaign won the Medical Marketing Association's 2007 International Award of Excellence (IN-AWE) Competition in the Photography category.
Paris (France) and Lausanne (Switzerland), 26 February 2007 - Ipsen grants Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product for aesthetic indications in Europe and certain other territories.
Follow us
Growing a responsible dermatological community
Discover some of the positive initiatives we are involved in across the world
We are committed
